SEC Form 4 · accession 0000899243-16-017930
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Pomerantz
Officer — President and CEO · Director
Period of report
Apr 7, 2016
Accepted (ET)
Apr 11, 2016 · 5:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 7, 2016 | M | 1,712 | $0.48 | A | 24,439 | D | |
| Common Stock | Apr 7, 2016 | M | 7,500 | $0.71 | A | 31,939 | D | |
| Common Stock | Apr 7, 2016 | S | 9,212 | $30.00 | D | 22,727 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.48 | Apr 7, 2016 | M | 1,712 | D | — | Nov 6, 2023 | Common Stock | 1,712 | 82,500 | D |
| Stock Option (right to buy)F3 | $0.71 | Apr 7, 2016 | M | 7,500 | D | — | Aug 7, 2024 | Common Stock | 7,500 | 1,668,251 | D |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on February 26, 2016.
- F2The option vested as to 25% of the shares subject to the option on September 9, 2014. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter.
- F3The option vested as to 25% of the shares subject to the option on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter.